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Abstract
Artemether and lumefantrine (AL), the active constituents of Coartem® exhibit complementary
pharmacokinetic profiles.Artemether is absorbed quickly; peak concentrations of artemether and
its main active metabolite,dihydroartemisinin (DHA) occur at approximately two hours post-dose,
leading to a rapid reduction in asexual parasite mass and a prompt resolution of symptoms.
Lumefantrine is absorbed and cleared more slowly (terminal elimination half-life 3–4 days in malaria
patients), and accumulates with successive doses, acting to prevent recrudescence by destroying
any residual parasites that remain after artemether and DHA have been cleared from the body.
Food intake significantly enhances the bioavailability of both artemether and lumefantrine,an effect
which is more apparent for the highly lipophilic lumefantrine. However, a meal with only a small
amount of fat (1.6 g) is considered sufficient to achieve adequate exposure to lumefantrine.The
pharmacokinetics of artemether or lumefantrine are similar in children, when dosed according to
their body weight, compared with adults. No randomized study has compared the pharmaco-
kinetics of either agent in pregnant versus non-pregnant women.Studies in healthy volunteers and
in children with malaria have confirmed that the pharmacokinetic characteristics of crushed
standard AL tablets and the newly-developed Coartem® Dispersible tablet formulation are similar.
Studies to date in healthy volunteers have not identified any clinically relevant drug-drug inter-
actions; data relating to concomitant administration of HIV therapies are limited. While dose-
response analyses are difficult to undertake because of the low rate of treatment failures under AL,
it appears that artemether and DHA exposure impact on parasite clearance time while lumefan-
trine exposure is associated with cure rate, consistent with their respective modes of action.
In conclusion, knowledge of the pharmacokinetic profiles of artemether and lumefantrine is
increasing within a range of settings,including infants and children.However,additional data would
be warranted to better characterize artemether and lumefantrine pharmacokinetics in patients
with hepatic impairment,in pregnant women,and in patients undergoing HIV/AIDS chemotherapy.
Open AccessThe complementary pharmacokinetics of
artemether and lumefantrine
Artemether and lumefantrine differ markedly in terms of
rate of absorption and elimination. When administered
as an oral combination, these differences act in a comple-
mentary manner to underpin the efficacy of Coartem®
(artemether/lumefantrine, AL) therapy. Artemether is
absorbed rapidly, reaching a peak concentration at
approximately two hours after dosing [1, 2]. It is quickly
hydrolysed to its main active metabolite, dihydro-
artemisinin (DHA), which also shows a maximum
concentration within two to three hours after dosing [1].
Both artemether and DHA are very active anti-malarial
agents that produce a reduction in asexual parasite mass
of approximately 10,000-fold per reproductive cycle [3],
accompanied by a prompt resolution of symptoms such
as fever. In contrast, the lumefantrine component of AL is
absorbed and cleared more slowly, acting to eliminate the
residual parasites that may remain after artemether and
DHA have been cleared from the body and thus prevent
recrudescence [1, 4]. Each tablet of AL (Coartem®) contains
20 mg of artemether and 120 mg of lumefantrine and the
standard regimen consists of twice-daily administration
for three days (six doses in total), covering at least two
asexual parasite life cycles with artemether and opti-
mising exposure to lumefantrine to prevent recru-
descence. Twice-daily dosing maintains artemether and
DHA concentrations at supratherapeutic levels [4] and a
standard six-dose, three-day regimen of AL is estimated to
reduce the parasite biomass by a factor of 108 [4].
A summary of pharmacokinetic parameters for arte-
mether, DHA and lumefantrine obtained in a series of
studies in healthy volunteers and malaria patients is
presented in Table 1. The time to peak plasma concen-
tration of artemether and DHA is similar in healthy
volunteers [1] and malaria patients [5, 6], but the peak
level may be higher in individuals with malaria compared
with healthy volunteers, possibly related to differences in
the volume of distribution and intestinal absorption in
malaria patients and the role of food in increasing oral
bioavailability [1]. Artemether and DHA exhibit con-
siderable variation in plasma concentration profiles both
between individuals and from dose to dose, largely
accounted for by their low and variable bioavailability
and the influence of food on absorption [1].
The peak concentration of lumefantrine occurs later, at
approximately six hours post-dosing in healthy volunteers
[1] and 3–4 hours in malaria patients [7]. Lumefantrine
has an elimination half-life of approximately six days in
healthy volunteers [8] and three to four days in patients
with  Plasmodium falciparum malaria [7, 9] (Table 1). As
observed with artemether, there is marked variability in
the absorption of lumefantrine, particularly in patients
with malaria, but this variation declines with successive
doses [7] and lumefantrine bioavailability increases sub-
stantially [1]. Indeed, bioavailability has been estimated
to increase three-fold for the third and fourth doses
compared with the first and second doses during
treatment with AL [2]. Febrile, nauseated patients tend to
eat little during the early acute stages of malaria, and a
return to normal food intake has been credited with
improving lumefantrine bioavailability during treatment
[1]. Because of its long elimination half-life, lumefantrine,
as expected, naturally accumulates during multiple
dosing [4], and the progressive increase in concentration
observed during the course of therapy means that
remaining parasites continue to be exposed to high levels
of lumefantrine as artemether and DHA are cleared from
the body.
The influence of food
Food (especially dietary fat) enhances the bioavailability
of artemether and lumefantrine, although this effect is
more apparent for lumefantrine [1, 7]. Administration of
AL to healthy volunteers at the same time as a high-fat
meal increases the bioavailability of artemether and
lumefantrine by two-fold and 16-fold, respectively,
compared with the fasted state [1]. This is particularly
relevant in view of the low food intake by many patients
during the acute phase of malaria. In a double-blind trial
of 260 patients with uncomplicated malaria in Thailand,
the extent and variability of lumefantrine absorption
improved with clinical recovery as normal food intake
was resumed [2]. The question arises how much dietary
fat is required to achieve adequate lumefantrine exposure
to achieve complete parasite clearance with AL. Ashley et
al performed a cross-over pharmacokinetic study in which
a single dose of AL was administered to 12 healthy
volunteers in conjunction with different volumes of soya
milk or with no milk [10]. A population model developed
from lumefantrine concentration measurements demon-
strated that 36 mL of soya milk (containing only 1.2 g of
fat) was associated with 90% of the lumefantrine expo-
sure obtained with 500 mL milk (16 g fat). The issue of
adequate lumefantrine absorption has also been assessed
in children with P. falciparum malaria in five African
countries [11]. Data on relative lumefantrine exposure in
315 children receiving AL within a randomized trial were
analysed according to concomitant consumption of
different foodstuffs, or no food at all. The relative increase
in mean lumefantrine absorption was 1.57 in patients
drinking milk and 2.74 in those eating pancakes versus
those who ate nothing, a much smaller difference than
that seen between fasting and fed volunteers [1].
Interestingly, all of the 20 children with malaria who
consumed no food at the time of any of the six AL doses
in this study experienced parasitological cure. Premji et al
have evaluated the typical fat content of African diets,
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fat intake in most sub-Saharan countries is in the range
15–30 g/day during breast feeding, >10 g/day in the post-
weaning phase, and 30–60 g/day for a normal diet,
concluding that fat intake is typically adequate for
optimal efficacy of lumefantrine. In a trial undertaken in
Uganda in which 957 patients were randomized to
receive AL either in hospital under supervision with a
specified meal containing 23 g fat or unsupervised at
home after the first dose with advice to take the drug with
a meal or breast milk, both groups had an identical 28-
day polymerase chain reaction (PCR)-corrected cure rate
in evaluable patients (100%) [13]. A pharmacokinetic
substudy revealed that lumefantrine plasma concen-
tration was higher in the supervised group [13, 14], but
the identical efficacy results showed that typical food or
milk consumption at home was sufficient to achieve
adequate lumefantrine exposure for optimal efficacy. It
appears that only a very small amount of dietary fat is
necessary to ensure adequate lumefantrine absorption
and that standard African diets or breast milk are
sufficient to meet this need. It is important, however, that
patients are encouraged to ensure normal food or milk
intake during AL administration if possible and to resume
intake quickly if food is declined during the acute phase
of the disease.
Pharmacokinetics of AL in specific patient
populations
Patients with renal or hepatic impairment
No specific pharmacokinetic studies have been performed
in individuals with renal insufficiency. However, renal
excretion plays no relevant role in AL clearance, as
demonstrated by a randomized, open-label, single-dose
trial involving 58 healthy volunteers, in which no quanti-
fiable concentrations of artemether or lumefantrine were
found in any urine sample [15]. Exposure to AL is,
therefore, not expected to be modified in subjects with
renal impairment compared to subjects with normal renal
function. Furthermore, in clinical studies the adverse
event profile of AL does not differ in patients with mild or
moderate renal impairment compared with patients with
normal renal function, although few patients with severe
renal impairment took part in these studies [16]. Clinical
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Table 1 – Pharmacokinetic parameters of artemether, dihydroartemisinin (DHA) and lumefantrine (mean or mean ± SD) among healthy volunteers and
patients with malaria receiving a six-dose, three-day regimen of AL 
Pharmacokinetic parameters
Artemether DHA
Food or fat  Country/ Cmax AUC t½ Cmax AUC t½
Subjects (n) content (g) Area (ng/mL) (μg·h/mL) (h) (ng/mL) (μg·h/mL) (h)
Healthy volunteers  ~65 ga Europe 30.8±25.4 61.4±87.5 2.0±1.2 84.5±26.5 178±71 1.2±0.4
(n=14) [22] 
Malaria patients  7 gd Thailand 34.8 66.4 1.5 165 367 1.3
(n=13) [6]
Malaria patients  Local  Thailand 66.2±54.3 211±109 2.2±1.0 205±102 604±259 1.6±0.4
(n=25) [5] standard food
Lumefantrine
Food or fat  Country/ Cmax AUC t½ Day 7 
Subjects (n) content (g) Area (μg/mL) (μg·h/mL) (day) concentration (ng/mL)
Healthy volunteers  ~65 ga Europe 10.0±5.5 383±304e 6.0±1.3 -
(n=14) [22] 
Malaria patients  Local  Thailand 9.0 561 3.2 -
(n=266) [7]  standard food
Malaria patients  23 gb Uganda 5.6±2.7 - - 460±288
(n=74) [13]
Malaria patients  6.4 gc Thailand 7.0 410 4.1 350
(n=17) [9]
Malaria patients  7 gd Thailand 7.34 252f 2.83 384
(n=13) [6]
aFDA breakfast = 2 eggs, 2 strips bacon, 1 slice of toast with butter, 2 hash potatoes, 240mL full-fat milk; b10g (300mL milk) + 13g (peanuts) or breast
milk; c200mL carton chocolate milk; d250mL chocolate milk; eAUC62h-last; fAUC60h-∞evidence also indicates that renal status does not
influences response rates or, indeed, that AL can affect
kidney function. Bakshi et al undertook a retrospective
analysis of 1,869 AL-treated patients, including 611
children ≥12 years [17], and found no significant changes
in renal function following treatment with AL. Accor-
dingly, no specific adjustment to AL dose is currently
requested for patients with mild to moderate renal
impairment, although caution should be exercized in
patients with severe renal dysfunction [16]. Similarly,
pharmacokinetic studies have not been carried out
specifically in the setting of hepatic impairment. As with
renal dysfunction, clinical studies have shown no differ-
ence in adverse events between patients with or without
mild or moderate hepatic impairment [16] and the
retrospective analysis of safety performed by Bakshi et al
did not reveal any difference in adverse events in patients
with hepatic insufficiency versus the general study
population [17]. Dose adjustment is not required in
patients with mildly or moderately restricted liver
function, although a cautious approach is advised in the
presence of severe hepatic impairment [16].
Overall, excellent tolerability has been observed in
clinical trials over a wide range of AL systemic exposure.
Taken together, the available data and the long post-
marketing experience suggest that the use of AL may be
safe in patients with some degree of renal or hepatic
impairment.
Paediatric patients
The greatest burden of malaria is borne by children, and
understanding the pharmacokinetics of AL in this
vulnerable group is critical. AL is indicated for use in
malaria paediatric patients weighing as little as 5 kg (i.e.
approximately two months of age), with dosing based on
body weight: one tablet per dose if body weight is 5–<15 kg,
two tablets per dose for 15–<25 kg, and three tablets per
dose for 25–<35 kg. Two clinical trials in Africa have
evaluated pharmacokinetic parameters in malaria paedia-
tric patients given crushed AL tablets [18, 19], which until
the introduction of Coartem® Dispersible was the stan-
dard method of drug administration in children. Results
showed that exposure to artemether, DHA, and lume-
fantrine when dosed on a mg/kg body weight basis in
paediatric malaria patients was comparable to that ob-
served in adult malaria patients. Lumefantrine mean Cmax
ranged between 4.71 and 9.37 μg/mL in paediatrics [18, 19]
and between 5.6 and 9.0 μg/mL in adult patients [7, 9,
13], while area under the curve (AUC)0-last values ranged
between 372 μg·h/mL and 699 μg·h/mL in children
[18, 19], and between 252 μg·h/mL and 561 μg·h/mL in
adults [6, 7]. Artemether and DHA exposure in children
[19] was also in line with that observed in adult malaria
patients [5]. When artemether or DHA exposure was
analysed according to body weight group, mean Cmax for
artemether was 188 ng/mL, 198 ng/mL and 174 ng/mL in
the 5–<15 kg, 15-<25 kg and 25–<35 kg groups,
respectively (54.7 ng/mL, 79.8 ng/mL and 68.4 ng/mL for
DHA). For lumefantrine, AUC0-last was 577 μg·h/mL in
the 5–<15 kg body weight group, and 699 μg·h/mL in the
15–<25 kg group. Exposure in the highest body weight
group (25–<35 kg) appeared to be higher (1150 μg·h/mL)
but due to the small number of plasma concentrations
collected in this group the finding was considered
unreliable [19].
Pregnancy
No randomized study has compared the pharmaco-
kinetics of artemether, DHA or lumefantrine in pregnant
and non-pregnant women. McGready and colleagues
have reported population-derived lumefantrine plasma
concentration time curves from 13 pregnant women in
Thailand [6]. They compared the results with a historical
group of 30 non-pregnant patients, most of whom were
male. Their comparison showed that lumefantrine
concentration curves were similar in the pregnant or non-
pregnant groups during the first five days after treatment,
after which total AUC (AUC60-∞) differed by only 6%
(237 μg·h/mL in pregnant patients versus 251 μg·h/mL
for the non-pregnant group). The peak lumefantrine
concentration (7.34 μg/mL) was within the range of
values reported in non-pregnant populations [7, 9, 13].
McGready et al observed that artemether and DHA Cmax
and AUC0-8 values were lower in their 13 pregnant
patients [6] versus another group of 25 male patients [5],
but levels were similar to those seen in healthy volunteers
[8]. Given the small patient population involved and the
known inter-subject and inter-study variation in
artemether pharmacokinetics, particularly if food intake
differs, between-trial comparisons of drug exposure
should be regarded with considerable caution. All 13
patients in the study by McGready et al achieved rapid
cure with a median parasite clearance time of two days.
Coartem® Dispersible
The new dispersible formulation of AL, developed
specifically for use in children to provide improved ease
of administration, has been evaluated in terms of its
pharmacokinetic profile relative to crushed tablets of AL,
the current standard of care in paediatrics. In an open-
label crossover study, 48 healthy adult volunteers were
given a single dose of the dispersible tablet or a crushed
standard tablet under fed conditions [20]. Exposure to
lumefantrine, artemether and DHA (AUC) was found to
be bioequivalent for the dispersible formulation and the
crushed standard tablet. Pharmacokinetic data from
children with malaria receiving the dispersible tablet are
available from a trial in five African countries in which
children ≤12 years old were randomized to dispersible or
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provided blood samples for measurement of artemether
and DHA concentration, and 625 patients provided one
sample each for measurement of lumefantrine
concentration. Mean artemether Cmax was 175±168
ng/mL for patients randomized to dispersible tablets and
190±168 ng/mL for those given crushed tablets. For DHA,
these values were 64.7±58.1 ng/mL and
63.7±65.0 ng/mL, respectively. Pharmacokinetics were
also assessed according to body weight group. Although
no statistical comparisons are available no descriptive
differences were apparent between body weight groups
for either artemether or DHA [19]. No difference in
lumefantrine pharmacokinetics was apparent between
treatment groups (Figure 1). Mean peak concentration for
lumefantrine over the six-dose treatment course was
6.3±4.6 μg/mL in the dispersible arm and 7.7±5.9 μg/mL
in the crushed tablets arm, while mean AUC was 574
μg·h/mL and 638 μg·h/mL, respectively.
Drug-drug interactions
Both artemether and lumefantrine are predominantly
metabolized by the cytochrome P450 3A4 (CYP3A4)
isoenzyme [1]. Although the likelihood of interactions
between AL and other drugs is minimal in view of its
short duration of administration and wide therapeutic
index, three pharmacokinetic and pharmacodynamic
drug-drug interaction studies with ketoconazole (a potent
CYP3A4 inhibitor), mefloquine, and quinine have been
conducted in healthy volunteers (Table 2). A randomized,
open-label crossover trial in 16 healthy volunteers
investigated the pharmacokinetics of artemether, DHA
lumefantrine after a single dose of AL alone or in
combination with multiple doses of ketoconazole [8].
There was a modest increase (2.4-fold) in artemether,
DHA, and lumefantrine exposure but this was not asso-
ciated with increased side effects or changes in
electrocardiographic parameters, and AL dose adjustment
is not considered necessary in falciparum malaria patients
receiving ketoconazole or other potent CYP3A4
inhibitors. For mefloquine, oral administration prior to a
standard six-dose regimen of AL in a randomized trial of
42 healthy volunteers had no statistically significant effect
on plasma concentration of artemether or the ratio of
artemether to DHA, but there was a 30–40% reduction in
lumefantrine peak concentration and exposure (AUC)
[21], possibly related to a mefloquine-induced decrease in
bile production. The effect was not considered clinically
relevant, and mefloquine pharmacokinetics were unaltered
[21]. Potential pharmacokinetic interactions between AL
and quinine have been assessed in a further randomized
study of healthy volunteers given a two-hour intravenous
infusion of quinine at the time of the last dose of AL in a
six-dose regimen [22]. Neither the pharmacokinetics of
lumefantrine nor the pharmacokinetics of quinine were
influenced by the presence of the other drug. Plasma
levels of artemether and DHA appeared to be lower
following administration of quinine, but this was not
considered to be clinically relevant.
The increased anti-malarial failure rates that are observed
in HIV-positive patients with malaria, due to an increased
parasite burden and the reduced host immunity
associated with HIV infection [23], mean that any drug-
drug interactions in this population may be particularly
relevant. Both anti-retroviral drugs and anti-malarial
agents are metabolized through cytochrome P450 path-
ways,  but due to variable pattern of inhibition and/or
induction of cytochrome P450 enzymes, the role of anti-
retrovirals in pharmacokinetic interactions is complex. To
date, only limited data exist with respect to co-adminis-
tration of AL and anti-retroviral drugs in either healthy
volunteers or HIV-infected patients. A recent study in 13
healthy volunteers [24] showed that coadministration of
the standard six-dose regimen of AL and lopinavir/
ritonavir (400/100 mg twice daily), resulted in a signifi-
cant 2.4-fold increase in lumefantrine exposure (AUC)
(p<0.01), a significant decrease in DHA exposure (p<0.02)
and in a non significant trend towards a decrease in
artemether exposure (p>0.05). However, there were no
changes in the DHA:artemether AUC ratios and AL did
not affect the pharmacokinetics of lopinavir or ritonavir.
The observed increase in lumefantrine exposure is not
surprising because ritonavir is a potent mechanism-based
inhibitor of CYP3A4, and this finding is in agreement
with data obtained when ketoconazole (another potent
CYP3A4 inhibitor) is coadministered with AL [8]. The
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Figure 1
Lumefantrine plasma concentration (mean ± SD) during
treatment with dispersible or crushed standard tablets of AL
in 625 children ≤12 years old (six doses over three days)
[19].safety profile of AL, combined with the fact that lume-
fantrine AUC is a key predictor of parasitological cure,
suggests that the observed increase in lumefantrine AUC
in the presence of lopinavir/ritonavir may be beneficial in
the treatment of malaria. The effects of ritonavir on drug-
metabolizing enzymes are varied and complex. Although
traditionally noted for its inhibitoryeffects on CYP3A and
CYP2D6, ritonavir is also an inducer of the CYP enzymes
3A, 1A2, 2B6, 2C9, and 2C19, P-gp (mixed induction/
inhibition) and uridine diphosphoglucuronyltransferase
(UGT) [25]. The decrease in artemether and DHA
exposure could have been due to the inducing effect of
ritonavir on these cytochrome P450 enzymes, and/or
UGT1A1 and UGT2B7, enzymes that are also involved in
the metabolism of artemether to DHA and/or conversion
of DHA to inactive metabolites [24]. Drug-drug inter-
actions in HIV-positive malaria patients between AL and
other anti-retrovirals or drugs used to treat HIV infection
are currently being further evaluated.
Dose-response relationships
The high response rates associated with the standard 6-
dose regimen of AL limits the scope to evaluate the
exposure-efficacy relationship because so few treatment
failures occur. However, Ezzet et al have reported data
from a study in which 260 patients with P. falciparum
malaria or mixed infection including P. falciparum
received only four doses of AL [2]. The derived pharmaco-
kinetic data for artemether, DHA and lumefantrine were
correlated with the 28-day PCR-corrected parasitological
cure rate and the time to parasite clearance, and results
showed that higher artemether and DHA AUC values
decreased parasite clearance time (p<0.001 for artemether
and p=0.003 for DHA) but were not associated with cure
rate. In contrast, higher lumefantrine AUC values
significantly increased the chance of cure but did not
influence the time to parasite clearance. These findings
are consistent with the mode of action of AL i.e. parasite
clearance within the first 48 hours of treatment is largely
due to artemether and DHA, while the long-lasting effect
of lumefantrine acts to clear infection and prevent
recrudescence. In their analysis, Ezzet et al identified the
median lumefantrine concentration at day 7 to be
280 ng/mL, and found that the incidence of 28-day PCR-
corrected cure was higher in patients with a day 7 level
above this threshold [2]. In a subsequent study, Ezzet et al
performed a pharmacodynamic analysis of lumefantrine
in 266 patients with uncomplicated falciparum malaria
receiving one of three different regimens of AL (four doses
over two days, a standard six doses over three days, or six
doses over five days) in a double-blind study [7]. Their
findings confirmed that the longer duration of exposure
to lumefantrine in the three- and five-day regimens was
associated with higher 28-day PCR-corrected parasitolo-
gical cure rates (83%, 97% and 99%, respectively; p<0.01).
The mean time for lumefantrine plasma concentration to
decline to 280 ng/mL was 10.5 days with the standard
three-day regimen. Pharmacokinetic data collected during
a prospective, randomized study of AL in Uganda are
consistent with these findings [14]. Among 479 adult and
paediatric patients for whom lumefantrine data were
available, median lumefantrine concentration at day 3
and day 7 in all three age groups (<5 years, 5–14 years and
≥15 years) was significantly lower in the intervention arm
(unsupervised dosing) than the control arm (supervised
dosing). Although the lumefantrine concentration at day
7 was more frequently below 280 ng/mL in the inter-
vention (unsupervised) arm (58.8%), a fairly high
proportion of the supervised patients (29.0%) also had
concentrations below this threshold. Nevertheless, across
the total study population the 28-day PCR-corrected cure
rate in evaluable patients was 100% in both arms i.e. all
patients achieved cure with no recrudescence [13]. White
et al [26] recommend the routine measurement of drug
concentration at day 7 as part of anti-malarial treatment.
However, a day 7 lumefantrine concentration threshold of
280 ng/mL as a pharmacokinetic predictor for treatment
response may not be applicable to all regions [13].
Indeed, more recently, a significantly lower threshold
(175 ng/mL) was proposed by Price et al [27] based on a
similar meta-analysis. Prediction of treatment failure
showed a sensitivity of only 75% and a specificity of 84%.
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Table 2 – Effect of concomitant medication (ketoconazole, mefloquine, quinine or lopinavir/ritonavir) on exposure to artemether, dihydroartemisinin
(DHA) and lumefantrine in studies undertaken in healthy volunteers
Change in exposure  Change in exposure  Change in exposure  Change in exposure 
Concomitant  to artemether  to DHA  to lumefantrine  to concomitant medication 
medication N (AUC) (AUC) (AUC) (AUC)a
Ketoconazole [8] 16 ↑2.4-fold ↑1.7-fold ↑1.7-fold Not measured
Mefloquine [21] 42 Unchanged Unchanged ↓32% Unchanged
Quinine [22] 42 ↓46% ↓37% Unchanged Unchanged
Lopinavir/ritonavir [24] 13 ↓35% ↓45% ↑2.4-fold Unchanged
a Ketoconazole, mefloquine, quinine or lopinavir/ritonavir, respectivelyConclusion
The pharmacokinetics of artemether and lumefantrine
allow the two agents to act synergistically, achieving quick
symptomatic relief with a high parasitological cure rate.
Artemether has a rapid onset of action that reduces
parasite biomass fast and resolves clinical symptoms.
Indeed patients feel better faster with artemisinin-derived
compounds than with any other class of anti-malarial
drug. Lumefantrine acts longer-term to eradicate the
remaining parasites over subsequent life cycles. The three-
day course of AL reduces the parasite burden to approxi-
mately 10–104 parasites, a residual pool which is exposed
to a high concentration of lumefantrine which has
accumulated over successive doses. Moreover, the rapid
parasite clearance achieved by artemether and DHA
means that despite the short elimination half-lives of
artemether and DHA, relatively few parasites are exposed
to lumefantrine alone (and none are exposed to
artemether or DHA alone), which would tend to reduce
selective pressure for development of resistance. The new
dispersible formulation shares these pharmacokinetic
characteristics.
While food intake enhances absorption, particularly for
lumefantrine, only a very small amount of fat is required
to achieve adequate absorption, and typical African diets
or breast milk are sufficient. Lastly, drug-drug interaction
studies to date have not revealed any clinically significant
interactions; trials with frequently-administered HIV
therapies are ongoing.
In conclusion, knowledge of the pharmacokinetic profiles
of artemether and lumefantrine is increasing within a
range of settings, including infants and children. However,
additional data would be warranted to better characterize
artemether and lumefantrine pharmacokinetics in patients
with hepatic impairment, in pregnant women, and in
patients undergoing HIV/AIDS chemotherapy.
Competing interests
The authors would like to acknowledge that Novartis
Pharma AG sponsored this supplement. GL is an
employee of Novartis Pharma AG; AD does not work for,
or represent in any way, Novartis Pharma AG.
Authors’ contributions
All authors met International Committee of Medical
Journal Editors criteria for authorship.
Acknowledgements
AD´s research is supported by European and Developing Countries
Clinical Trail Partnership Senior Fellowship (Grant # 2004.2.C.f1) and
Howard Hughes Medical Institution International Scholarship (Grant #
55005502).
The authors would like to thank Caroline Dunstall,who provided editorial
assistance with funding from Novartis Pharma AG.
This article is part of Malaria Journal Volume 8 Supplement 1: Coartem®:
reviewing the impact on the malaria landscape. The full contents of the
supplement are available online at http://www.malariajournal.com/
supplements/8/S1. Publication of the supplement has been sponsored by
Novartis Pharma AG.
References
1. White NJ, van Vugt M, Ezzet F: Clinical pharmacokinetics and
pharmacodynamics and pharmacodynamics of artemether-
lumefantrine. Clin Pharmacokinet 1999, 37:105-125.
2. Ezzet F, Mull R, Karbwang J: Population pharmacokinetics and
therapeutic response of CGP 56697 (artemether +
benflumetol) in malaria patients. Br J Clin Pharmacol 1998; 46:
553-561.
3. White NJ: Preventing antimalarial drug resistance through
combinations. Drug Resistance Updates 1998, 1:3-9.
4. Kokwaro G, Mwai L, Nzila A: Artemether/lumefantrine in the
treatment of uncomplicated falciparum malaria. Expert Opin
Pharmacother 2007, 8:75-94.
5. Lefèvre G, Looareesuwan S,Treeprasertsuk S, Krudsood S, Silacham-
roon U, Gathmann I, Mull R, Bakshi R: A clinical and pharmaco-
kinetic trial of six doses of artemether-lumefantrine for
multidrug-resistant  plasmodium falciparum malaria in
Thailand. Am J Trop Med Hyg 2001, 64:247-256.
6. McGready R, Stepniewska K, Lindegardh N, Ashley EA, La Y,
Singhasivanon P, White NJ, Nosten F: The pharmacokinetics of
artemether and lumefantrine in pregnant women with un-
complicated falciparum malaria. Eur J Clin Pharmacol 2006, 62:
1021-1031.
7. Ezzet F,van Vugt M,Nosten F,Looareesuwan S,White NJ:Pharmaco-
kinetics and pharmacodynamics of lumefantrine (benflu-
metol) in acute falciparum malaria. Antimicrob Agents Chemother
2000, 44:697-704.
8. Lefèvre G, Carpenter P, Souppart C, Schmidli H, McLean M, Stypinski
D: Pharmacokinetics and electrocardiographic pharmaco-
dynamics of artemether-lumefantrine (Riamet®) with con-
comitant administration of ketoconazole in healthy subjects.
Br J Clin Pharmacol 2002, 54:485-492.
9. Ashley EA, Stepniewska K, Lindegårdh N, McGready R,Annerberg A,
Hutagalung R, Singtoroj T, Hla G, Brockman A, Proux S,
Wilahphaingern J, Singhasivanon P, White NJ, Nosten F:
Pharmacokinetic study of artemether–lumefantrine given
once daily for the treatment of uncomplicated multidrug-
resistant falciparum malaria. Trop Med Int Health 2007, 12:201-
208.
10. Ashley EA, Stepniewska K, Lindegårdh N, Annerberg A, Kham A,
Brockman A,Singhasivanon P,White NJ,Nosten F:How much fat is
necessary to optimize lumefantrine oral bioavailability? Trop
Med Int Health 2007, 12:195-200.
11. Borrmann S, Sallas WM, Marrast A-C, Lefèvre G, Kern SE: Exposure
to lumefantrine in infants and children receiving
artemether-lumefantrine for uncomplicated malaria:impact
of African diet components. American Society of Tropical Medicine
and Hygiene Annual Meeting,7-11 December 2008,New Orleans,USA
12. Premji ZG,Abdulla S, Ogutu B, Ndong A, Falade CO, Sagara I, Mulure
N, Nwaiwu O, Kokwaro G: The content of African diets is
adequate to achieve optimal efficacy with fixed-dose
artemether-lumefantrine: a review of the evidence. Malar J
2008, 7:244.
13. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E,
Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L,Taylor W,
Checchi F,Guthmann JP:Supervised versus unsupervised intake
of six-dose artemether-lumefantrine for treatment of acute,
uncomplicated Plasmodium falciparum malaria in Mbarara,
Uganda: a randomized trial. Lancet 2005, 365:1467-1473.
14. Checchi F, Piola P, Fogg P, Bajunirwe F, Biraro S, Grandesso F, Ruzagira
E,Babigumira J,Kigozi I,Kiguli J,Kyomuhendo J,Ferradini L,Taylor WR:
Supervised versus unsupervised antimalarial treatment with
six-dose artemether-lumefantrine: pharmacokinetics and
dosage-related findings from a clinical trial in Uganda.Malar J
2006, 5:59.
15. Data on file, Novartis Pharma AG. Study CCOA566B2106
16. Coartem® Prescribing Information, Novartis Pharmaceuticals
Corporation. Updated April 2009.
Malaria Journal 2009, 8(Suppl 1):S4 http://www.malariajournal.com/content/8/S1/S4
Page 7 of 8
(page number not for citation purposes)17. Bakshi R, Hermeling-Fritz I, Gathmann I, Alteri E: An integrated
assessment of the clinical safety of artemether-lumefan-
trine: a new oral fixed-dose combination antimalarial drug.
Trans R Soc Trop Med Hyg 2000, 94:419-424.
18. Data on file, Novartis Pharma AG. Study CCOA566A2403
19. Abdulla A, Sagara I, Borrmann S, D’ Alessandro U, González R, Hamel
M , Ogutu B, Mårtensson A, Lyimo J, Maiga H, Sasi P, Nahum A, Bassat
Q, Juma E, Otieno L, Björkman A, Beck HP, Andriano K, Cousin M,
Lefèvre G,Ubben D,Premji Z:Efficacy and safety of artemether-
lumefantrine dispersible tablet in African infants and
children with uncomplicated malaria: a randomised,
investigator-blinded, multi-centre comparison with the
crushed commercial tablet. The Lancet 2008, 372:1819-1827.
20. Lefèvre G, Abdulla S, Lyimo J, Agyemang A, Reynolds C, Pascoe S,
Fitoussi S, Yeh C-M, Nuortti M, Rivière G-J, Séchaud R: Early
development of the new artemether-lumefantrine disper-
sible tablet: palatability and pharmacokinetics in healthy
volunteers. American Society of Tropical Medicine and Hygiene Annual
Meeting, 7-11 December 2008, New Orleans, USA.
21. Lefèvre G,Bindschedler M,Ezzet F,Schaeffer N,Meyer I,Thomsen MS:
Pharmacokinetic interaction trial between co-artemether
and mefloquine. Eur J Pharm Sci 2000, 10:141-151.
22. Lefèvre G, Carpenter P, Souppart C, Schmidli H, Martin JM, Lane A,
Ward C, Amakye D: Interaction trial between artemether-
lumefantrine (Riamet) and quinine in healthy subjects. J Clin
Pharmacol 2002, 42:1147-1158.
23. World Health Organization: Guidelines for treatment of malaria.
Geneva:World Health Organization; 2006.
24. German P, Parikh S, Lawrence J, Dorsey G, Rosenthal P, Havlir D,
Charlebois E,Hanpithakpong W,Lindegardh N,Aweeka FT:Lopinavir/
ritonavir affects pharmacokinetic exposure of artemether/
lumefantrine in HIV-uninfected healthy volunteers. J Acquir
Immune Defic Syndr 2009, 51:424-429.
25. Foisy MM,Yakiwchuk EM,Hughes CA:Induction effects of ritona-
vir: implications for drug interactions. Ann Pharmacother 2008,
42:1048-59.
26. White NJ,Stepniewska K,Barnes K,Price RN,Simpson J:Simplified
antimalarial therapeutic monitoring: using the day-7 drug
level? Trends Parasitol 2008, 24:159-163.
27. Price RN,Uhlemann AC,van Vugt M,Brockman A,Hutagalung R,Nair
S,Nash D,Sinhasivanon P,Anderson TJC,Krishna S,White NJ,Nosten
F: Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in
multidrug-resistant Plasmodium falciparum malaria. Clin Infect
Dis 2006, 42:1570-1577.
Malaria Journal 2009, 8(Suppl 1):S4 http://www.malariajournal.com/content/8/S1/S4
Page 8 of 8
(page number not for citation purposes)